Biomarkers Consortium - High Definition Single Cell Analysis of Blood and Tissue Biopsies in Patients with Colorectal Cancer Undergoing Hepatic Metastasectomy

Colorectal cancer (CRC) is the second leading cause of cancer deaths in western countries. The five-year survival rate in early-stage CRC patients falls from 90% to 60% with lymph node involvement and to 10% with metastases. Early detection and treatment of mCRC would benefit from an easily obtainable biomarker signature (bio-signature) to characterize patient subpopulations. The core hypothesis for this project is that a liquid biopsy can serve as a source of rare circulating cells (CTCs) to represent or complement the traditional solid biopsy. The project is an observational clinical study in two stages, with a possible third stage, to sample CTCs and solid tissue from patients with metastatic colorectal cancer (mCRC) undergoing liver resection. Cell-free DNA will also be collected as part of the liquid biopsies for later analysis if warranted.

Goals

  • Determine the level of correlation between liquid (blood) and solid (tumor touch prep) biopsies.
  • Develop biosignatures for liquid biopsy representation of solid biopsies through genomic, proteomic, and morphometric profiling of primary tumor, circulating cells, and metastases.
  • Correlate multivariate profiling to outcome; predict recurrence.

Results & Accomplishments

Media

University of Southern California Press Release (May 4, 2016):

Partners

AbbVie Inc.
Amgen, Inc.
Baylor College of Medicine
Daiichi Sankyo, Inc.
Eli Lilly and Company
Food and Drug Administration
Johns Hopkins University
Memorial Sloan Kettering Cancer Center
National Cancer Institute
Scripps Health
University of Southern California

Contact

Stacey J. Adam, PhD, Scientific Program Manager, Cancer; sadam@fnih.org
Dana E. Connors, Scientific Project Manager, Cancer; dconnors@fnih.org